Eric W Tai1, Kevin C Ward2, Audrey Bonaventure3, David A Siegel4, Michel P Coleman3. 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Georgia Center for Cancer Statistics, Emory University, Atlanta, Georgia. 3. Cancer Survival Group, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. 4. Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia.
Abstract
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. This report describes the survival of children with ALL in the United States using the most comprehensive and up-to-date cancer registry data. METHODS: Data from 37 state cancer registries that cover approximately 80% of the US population were used. Age-standardized survival up to 5 years was estimated for children aged 0-14 years who were diagnosed with ALL during 2 periods (2001-2003 and 2004-2009). RESULTS: In total, 17,500 children with ALL were included. The pooled age-standardized net survival estimates for all US registries combined were 95% at 1 year, 90% at 3 years, and 86% at 5 years for children diagnosed during 2001-2003, and 96%, 91%, and 88%, respectively, for those diagnosed during 2004-2009. Black children who were diagnosed during 2001-2003 had lower 5-year survival (84%) than white children (87%) and had less improvement in survival by 2004-2009. For those diagnosed during 2004-2009, the 1-year and 5-year survival estimates were 96% and 89%, respectively, for white children and 96% and 84%, respectively, for black children. During 2004-2009, survival was highest among children aged 1 to 4 years (95%) and lowest among children aged <1 year (60%). CONCLUSIONS: The current results indicate that overall net survival from childhood ALL in the United States is high, but disparities by race still exist, especially beyond the first year after diagnosis. Clinical and public health strategies are needed to improve health care access, clinical trial enrollment, treatment, and survivorship care for children with ALL. Cancer 2017;123:5178-89. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. This report describes the survival of children with ALL in the United States using the most comprehensive and up-to-date cancer registry data. METHODS: Data from 37 state cancer registries that cover approximately 80% of the US population were used. Age-standardized survival up to 5 years was estimated for children aged 0-14 years who were diagnosed with ALL during 2 periods (2001-2003 and 2004-2009). RESULTS: In total, 17,500 children with ALL were included. The pooled age-standardized net survival estimates for all US registries combined were 95% at 1 year, 90% at 3 years, and 86% at 5 years for children diagnosed during 2001-2003, and 96%, 91%, and 88%, respectively, for those diagnosed during 2004-2009. Black children who were diagnosed during 2001-2003 had lower 5-year survival (84%) than white children (87%) and had less improvement in survival by 2004-2009. For those diagnosed during 2004-2009, the 1-year and 5-year survival estimates were 96% and 89%, respectively, for white children and 96% and 84%, respectively, for black children. During 2004-2009, survival was highest among children aged 1 to 4 years (95%) and lowest among children aged <1 year (60%). CONCLUSIONS: The current results indicate that overall net survival from childhood ALL in the United States is high, but disparities by race still exist, especially beyond the first year after diagnosis. Clinical and public health strategies are needed to improve health care access, clinical trial enrollment, treatment, and survivorship care for children with ALL. Cancer 2017;123:5178-89. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Amaranto Suarez; Martha Piña; Diana X Nichols-Vinueza; John Lopera; Lyda Rengifo; Mauricio Mesa; Marcela Cardenas; Lisa Morrissey; Galo Veintemilla; Martha Vizcaino; Ligia Del Toro; Victor Vicuna; Jorge Fernandez; Donna Neuberg; Kristen Stevenson; Alejandro Gutierrez Journal: Pediatr Blood Cancer Date: 2015-03-24 Impact factor: 3.167
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Monika L Metzger; Scott C Howard; Ligia C Fu; Armando Peña; Rene Stefan; Michael L Hancock; Zhe Zhang; Ching Hon Pui; Judy Wilimas; Raul C Ribeiro Journal: Lancet Date: 2003-08-30 Impact factor: 79.321
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Ronay Thomas; Wendy S W Wong; Reem Saadon; Thierry Vilboux; John Deeken; John Niederhuber; Suchitra K Hourigan; Elizabeth Yang Journal: Pediatr Hematol Oncol Date: 2020-05-19 Impact factor: 1.969
Authors: Joshua P Muñiz; John P Woodhouse; Amy E Hughes; Sandi L Pruitt; Karen R Rabin; Michael E Scheurer; Philip J Lupo; Jeremy M Schraw Journal: Pediatr Hematol Oncol Date: 2022-03-09 Impact factor: 2.070
Authors: Staci D Arnold; Ruta Brazauskas; Naya He; Yimei Li; Matt Hall; Yoshiko Atsuta; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Shahrukh Hashmi; Susan Parsons; William A Wood; Amir Steinberg; César O Freytes; Christopher E Dandoy; David I Marks; Hillard M Lazarus; Hisham Abdel-Azim; Menachem Bitan; Miguel Angel Diaz; Richard F Olsson; Usama Gergis; Adriana Seber; Baldeep Wirk; C Fred LeMaistre; Celalettin Ustun; Christine Duncan; David Rizzieri; David Szwajcer; Franca Fagioli; Haydar Frangoul; Jennifer M Knight; Rammurti T Kamble; Paulette Mehta; Raquel Schears; Prakash Satwani; Michael A Pulsipher; Richard Aplenc; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2020-05-25 Impact factor: 5.742
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167
Authors: Melanie D Whittington; R Brett McQueen; Daniel A Ollendorf; Varun M Kumar; Richard H Chapman; Jeffrey A Tice; Steven D Pearson; Jonathan D Campbell Journal: JAMA Pediatr Date: 2018-12-01 Impact factor: 16.193
Authors: Hannah K Weir; Sherri L Stewart; Claudia Allemani; Mary C White; Cheryll C Thomas; Arica White; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860